We aim to dramatically raise IVF birth rates by giving clinicians tools to select the most competent eggs (oocytes) and most viable embryos.
GemARTviaSM, our first clinical test, will identify embryos most likely to produce a baby.
We aim to improve fetal health and reduce physical and emotional burdens on women undergoing infertility treatment by giving clinicians solutions to select the healthiest oocytes and embryos.
GemART23SM, our second clinical test, will screen embryos to ensure they are free of chromosomal abnormalities such as trisomy 21 (Down syndrome).
- INNOVATIVE: Our technology leverages the gene expression of special cells, called cumulus cells. These cells are essential for successful oocyte development, but regularly discarded during the IVF process.
- PREDICTIVE: Our tests use proprietary biomarkers and algorithms that produce clear, reproducible, and accurate information.
- NONINVASIVE: Because our technology utilizes cumulus cells, no embryonic cells are destroyed and no part of the oocyte is pierced or biopsied.
- UNOBTRUSIVE: Our tests have a minimal impact on clinical workflow and virtually no special clinical training or equipment are required prior to application.